Tahereh Nazary

Dr. Tahereh Nazary


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2023 in Archives of Virology
Verified
Journal Article
Open access
PDF file
TNTahereh Nazary
Tahereh Nazary
AAAzin Aghamajidi
Azin Aghamajidi
MDMaryam Dorfaki
Maryam Dorfaki
FKFatemeh Keshavarz
Fatemeh Keshavarz
ZSZahra Shafaghat
Zahra Shafaghat
RJReza Jafari
Reza Jafari
B lymphocytes play a vital role in the human defense against viral infections by producing specific antibodies. They are also critical for the prevention of infectious diseases by vaccination, and their activation influences the efficacy of the vaccination. Since the beginning of coronavirus disease 2019 (COVID-19), which became the main concern of the world health system, many efforts have been made to treat and prevent the disease. However, for the development of successful therapeutics and vaccines, it is necessary to understand the interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, and the immune system. The innate immune system provides primary and nonspecific defense against the virus, but within several days after infection, a virus-specific immune response is provided first by antibody-producing B cells, which are converted after the resolution of disease to memory B cells, which provide long-term immunity. Although a failure in B cell activation or B cell dysfunction can cause a severe form of the disease and also lead to vaccination inefficiency, some individuals with B cell immunodeficiency have shown less production of the cytokine IL-6, resulting in a better disease outcome. In this review, we present the latest findings on the interaction between SARS-CoV-2 and B lymphocytes during COVID-19 infection.

2 September 2020 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
TNTahereh Nazary
Tahereh Nazary
LALadan Gol Mohammad pour Afrakoti
Ladan Gol Mohammad pour Afrakoti
ASAbbas Shahi
Abbas Shahi
RSReza Shabanian
Reza Shabanian
AAAliakbar Amirzargar
Aliakbar Amirzargar
Myocarditis is an inflammatory disease of the myocardium with lymphocyte infiltration and myocyte necrosis leading to a wide range of clinical presentations including heart failure, arrhythmia, and cardiogenic shock. Infectious and noninfectious agents may trigger the disease. The fact that immunosuppressive drugs are useful in several kinds of autoimmune myocarditis is proof of the autoimmune mechanisms involved in the development of myocarditis. Pathogenic mechanisms in myocardial inflammation are including inflammasome activation followed by myocyte destruction, myocarditis, and pericarditis. Intravenous immunoglobulin (IVIG) is a serum product made up of immunoglobulins, widely used in a variety of diseases. This product is effective in several immune-mediated pathologies. As well as the determined usage of IVIG in Kawasaki disease, IVIG may be useful in several kinds of heart failure including fulminant myocarditis, acute inflammatory cardiomyopathy, Giant Cell Myocarditis, and peripartum cardiomyopathy. Generally, IVIG is used in two different doses of low dose (200 to 400 mg/kg) and high dose (2 g/kg) regimen. The exact therapeutic effects of IVIG are not clear, however over the last decades, our knowledge about its mechanism of function has greatly enhanced. IVIG administration should be based on the accepted protocols of its transfusion. In this review article, we try to provide an overview of the different kinds of myocarditis, pathologic mechanisms and their common treatments and evaluation of the administration of IVIG in these diseases. Furthermore, we will review current protocols using IVIG in each disease individually.

10 December 2014
Verified
Journal Article
Open access
TNTahereh Nazary
Tahereh Nazary
MMM Moogooei
M Moogooei
SNS Nozari
S Nozari
Routine screening for distress is internationally recommended as a necessary standard for good cancer care given its high prevalence and negative consequences on quality of life. This study attempts to support validation of Distress Thermometer (DT) in Shiraz, Iran and in the second step to investigate privilege/priority of DT over other referent criterion measures. In total, 58 outpatients with cancer were recruited from AMIR Oncology hospital in Shiraz, Iran. Each participant completed the DT and a list of 34 possible cancer-related problems (the Problem List), the Hospital Anxiety and Depression Scale (HADS), the 18-item Brief Symptom Inventory (BSI-18), and a short visual analog scale to determine the understandability of the tools. Characteristic analysis revealed that DT cutoff scores ≥4 and ≥5 had optimal sensitivity and specificity relative to both HADS and BSI-18 cutoff scores for general caseness and more severe psychological distress, respectively. Patients with DT scores ≥4 (cases) were more likely to be women suffering from psychological problems in the past experience stressful events in the 3 years ago and encounter more family, emotional, and physical issue related to cancer or cancer treatment (p=0.02). Patients indicated that the DT was easier to fill out and to understand than the HADS, but not the BSI-18. The DT was identified as a simple and effective screening instrument for detecting distress in Iranian cancer patients as a first step toward more properly referring those in need to psychosocial intervention.